1. The Importance of Testosterone Control in Prostate Cancer
Bertrand Tombal 
European Urology Supplements 
Volume 6, Issue 15, Pages (September 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Approximately 1–12.5% of the patients on conventional LHRH agonists do not achieve testosterone castration levels ≤50ng/dl. Deep orange indicate new data presented at the European Association of Urology 2007 meeting.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
About 13–40% of the patients on conventional LHRH agonists do not reach testosterone castration levels ≤20ng/dl. Deep orange indicate new data presented at the European Association of Urology 2007 meeting.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Approximately 10% of the patients on conventional LHRH agonists show injection-related testosterone escapes (miniflares), whereas 2–24% encounter breakthrough testosterone escapes. Deep orange indicate new data presented at the European Association of Urology 2007 meeting.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions